Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CVM vs BCRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BCRX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

BCRX Overall Winner 6-Pillar Tally: CVM 0 – 6 BCRX Matrix Metrics: CVM 3 – 7 BCRX

As of Nov 16, 2026, BioCryst Pharmaceuticals Inc (BCRX) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas BCRX carries 43.3/100 (HOLD) at $7.53 (8.9x Forward P/E, 48.8% operating margin).

  • Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. BCRX 43.3/100 HOLD), BCRX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (48.8% vs. 0.0% operating margin) and revenue trajectory (+13.1% vs. -62.7% YoY).
  • Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile BCRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CVM vs BCRX
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $1.46 · SMA50: $1.66
BCRX NASDAQ Head-to-Head Winner
BioCryst Pharmaceuticals Inc
Biological Products, (No Disgnostic Substances)
$7.53
-1.05% 1D
Market Cap $1.9B
TTM Revenue $962M
Forward P/E 8.9x
Beta / 30D Vol 0.77β · 42% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 24.0 Fund 59.0 Flow 67.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.8%), weak momentum, RSI 39
RSI-14: 39.3 · SMA20: $7.92 · SMA50: $8.18

6-Pillar Scorecard Institutional Category Breakdown (CVM 0 – 6 BCRX)

Columns: Metric · CVM · BCRX
1. Valuation Multiples BCRX
Forward P/E 23.0x 8.9x
Trailing P/E 23.0x 13.0x
PEG Ratio 1.12x 9.39x
EV / Revenue N/M 2.7x
2. Growth & Scale BCRX
Revenue Growth (YoY) -62.7% +13.1%
Earnings Growth (YoY) +0.0% +133.3%
TTM Revenue (USD) $28,558 $962M
Market Cap $20.9M $1.9B
3. Profitability & Quality BCRX
Gross Margin N/A 78.1%
Operating Margin 0.0% 48.8%
Net Profit Margin 0.0% -37.4%
Return on Equity (ROE) -252.5% -1925.4%
4. Balance Sheet & Cash Flow BCRX
Cash Generation (TTM) -$17M $366M
Cash Flow Margin N/A 38.0%
Net Cash / Leverage $6.6M Net Debt (1.24x D/E) $687M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BCRX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) 60.0% (12th %ile)
Put/Call OI Skew N/A 0.24x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat BCRX
OpEx & R&D Intensity N/A 29.3% of Rev ($282M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CVM (3) vs BCRX (7)
Institutional Metric CVM BCRX Criterion Row Edge
Market Capitalization
Scale
$20.9M $1.9B Larger Scale BCRX
Trailing P/E Ratio
Valuation
23.0x 13.0x Lower Multiple BCRX
Forward P/E Ratio
Valuation
23.0x 8.9x Lower Multiple BCRX
Revenue Growth (YoY)
Growth
-62.7% +13.1% Higher Growth BCRX
Operating Margin (TTM)
Profitability
0.0% 48.8% Higher Margin BCRX
Net Profit Margin
Profitability
0.0% -37.4% Higher Margin CVM
Return on Equity (ROE)
Capital Efficiency
-252.5% -1925.4% Higher ROE CVM
52-Week Range Position
Momentum
10% ($1–$8) 26% ($6–$11) Stronger Trend BCRX
Beta / 30D Volatility
Risk Regime
0.65β · 120% Vol 0.77β · 42% Vol Lower Realized Risk BCRX
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 43.3 / 100 (HOLD) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
$28,558 $962M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 78.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.12x PEG · N/M EV/Rev 9.39x PEG · 2.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($6.6M Net Debt (1.24x D/E)) $366M ($687M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BCRX +7.83 pp
CVM: -11.17% · BCRX: -3.34%
3M Horizon CVM +22.37 pp
CVM: +0.0% · BCRX: -22.37%
6M Horizon CVM +8.49 pp
CVM: -7.56% · BCRX: -16.05%
1Y Horizon BCRX +82.34 pp
CVM: -75.98% · BCRX: +6.36%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CVM Revenue BCRX Revenue CVM Op. Margin BCRX Op. Margin Margin Leader
FY2018 N/A $20M N/A -456.2% BCRX
FY2019 N/A $50M N/A -203.7% BCRX
FY2020 N/A $20M N/A -981.1% BCRX
FY2021 N/A $160M N/A -113.1% BCRX
FY2022 N/A $270M N/A -54.8% BCRX
FY2023 N/A $330M N/A -31.3% BCRX
FY2024 N/A $450M N/A -0.6% BCRX
FY2025 N/A $870M N/A 39.0% BCRX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BCRX BREAKDOWN
92d in phase · OBV DISTRIBUTION
Current IV 60.0%
IV Percentile 12th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BCRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BCRX Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.9B market capitalization and 48.8% operating margin.
OpEx & R&D Reinvestment 29.3% of Rev ($282M)
90D Engineering Disclosures 0 Published

Investor FAQ CVM vs BCRX Key Questions & Quantitative Answers

As of Nov 16, 2026, BioCryst Pharmaceuticals Inc (BCRX) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas BCRX carries 43.3/100 (HOLD) at $7.53 (8.9x Forward P/E, 48.8% operating margin). Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. BCRX 43.3/100 HOLD), BCRX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (48.8% vs. 0.0% operating margin) and revenue trajectory (+13.1% vs. -62.7% YoY). Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile BCRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BCRX leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with BCRX at +13.1% YoY revenue growth and +133.3% YoY earnings growth on $962M TTM revenue (78.1% gross margin, 48.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CVM cumulative revenue shifted N/A while BCRX shifted +4250.0%. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus 29.3% of Rev ($282M) (0 disclosures) for BCRX.

BCRX screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas BCRX trades at 8.9x Forward P/E, 13.0x Trailing P/E, 9.39x PEG, and 2.7x EV/Revenue (38.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus BCRX (-1925.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk). By comparison, BCRX carries 60.0% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.77β · 42% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.